Janus Kinase Inhibitor [EPC]

160751 reported adverse events

Drugs of this class: ABROCITINIB BARICITINIB TOFACITINIB DELGOCITINIB RUXOLITINIB UPADACITINIB

These side effects are most commonly reported by patients taking drugs of the Janus Kinase Inhibitor [EPC] class:

# Side effect Count
0 OFF LABEL USE 16904
1 FATIGUE 9188
2 DEATH 8644
3 DRUG INEFFECTIVE 7606
4 PAIN 7546
5 ARTHRALGIA 6426
6 DIARRHOEA 4683
7 HEADACHE 4618
8 COVID-19 4395
9 PNEUMONIA 4392
See all common reactions for Janus Kinase Inhibitor [EPC]

Drugs of the Janus Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MYELOFIBROSIS 947 0.3129
1 SPLENOMEGALY 1832 0.1562
2 PLATELET COUNT INCREASED 1656 0.1269
3 SPINAL OPERATION 1115 0.0904
4 PRODUCT AVAILABILITY ISSUE 2040 0.0895
5 BLOOD COUNT ABNORMAL 1157 0.0762
6 KNEE ARTHROPLASTY 1497 0.0710
7 SKIN CANCER 1080 0.0501
8 SURGERY 2766 0.0471
9 WHITE BLOOD CELL COUNT INCREASED 1583 0.0412
See all enriched reactions for Janus Kinase Inhibitor [EPC]